{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T06:20:53Z","timestamp":1787466053186,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Mol Morphol"],"DOI":"10.1007\/s00795-026-00469-z","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:49:26Z","timestamp":1787464166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid metabolic reprogramming in ovarian cancer: molecular mechanisms and therapeutic implications"],"prefix":"10.1007","author":[{"given":"Naomi","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Maejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029\u20131033","journal-title":"Science"},{"key":"469_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"469_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"469_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12964-023-01449-x","volume":"22","author":"X Li","year":"2024","unstructured":"Li X et al (2024) Glutamine addiction in tumor cells: oncogene regulation and clinical treatment. Cell Commun Signal 22:12","journal-title":"Cell Commun Signal"},{"key":"469_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/bjc.2017.374","volume":"118","author":"K Stoiber","year":"2018","unstructured":"Stoiber K (2018) Targeting de novo lipogenesis as a novel approach in anti-cancer therapy. Br J Cancer 118:43\u201351","journal-title":"Br J Cancer"},{"key":"469_CR6","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"593017","DOI":"10.3389\/fonc.2020.593017","volume":"10","author":"Z Ji","year":"2020","unstructured":"Ji Z, Shen Y, Feng X (2020) Deregulation of lipid metabolism: the critical factors in ovarian cancer. Front Oncol 10:593017","journal-title":"Front Oncol"},{"issue":"3","key":"469_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.stem.2016.11.004","volume":"20","author":"J Li","year":"2017","unstructured":"Li J et al (2017) Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell 20(3):303","journal-title":"Cell Stem Cell"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","volume":"5","author":"S Beloribi-Djefaflia","year":"2016","unstructured":"Beloribi-Djefaflia S et al (2016) Lipid metabolic reprogramming in cancer cells. Oncogenesis 5:e189","journal-title":"Oncogenesis"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3892\/or.2013.2575","volume":"30","author":"LY Nie","year":"2013","unstructured":"Nie LY et al (2013) Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep 30:1346\u20131354","journal-title":"Oncol Rep"},{"key":"469_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/onc.2015.179","volume":"35","author":"SJH Ricoult","year":"2016","unstructured":"Ricoult SJH et al (2016) Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene 35:1250\u20131260","journal-title":"Oncogene"},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/cancers13153737","volume":"13","author":"P Linn","year":"2021","unstructured":"Linn P et al (2021) Targeting RB1 loss in cancers. Cancers (Basel) 13:3737","journal-title":"Cancers (Basel)"},{"key":"469_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1194\/jlr.E069880","volume":"57","author":"JE Schaffer","year":"2016","unstructured":"Schaffer JE (2016) Lipotoxicity: many roads to cell dysfunction and cell death. J Lipid Res 57:1327\u20131328","journal-title":"J Lipid Res"},{"key":"469_CR14","doi-asserted-by":"publisher","first-page":"39970","DOI":"10.18632\/oncotarget.9461","volume":"7","author":"J Huang","year":"2016","unstructured":"Huang J et al (2016) SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. Oncotarget 7:39970\u201339979","journal-title":"Oncotarget"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ejmech.2018.09.001","volume":"157","author":"C Granchi","year":"2018","unstructured":"Granchi C et al (2018) ATP citrate lyase inhibitors: an anticancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem 157:1276\u20131291","journal-title":"Eur J Med Chem"},{"key":"469_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2005.09.008","volume":"8","author":"G Hatzivassiliou","year":"2005","unstructured":"Hatzivassiliou G et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311\u2013321","journal-title":"Cancer Cell"},{"key":"469_CR17","doi-asserted-by":"publisher","first-page":"24990","DOI":"10.1074\/jbc.M112.340083","volume":"287","author":"A Mukherjee","year":"2012","unstructured":"Mukherjee A et al (2012) Lysophosphatidic acid activates lipogenic pathways in ovarian cancer cells. J Biol Chem 287:24990\u201325000","journal-title":"J Biol Chem"},{"key":"469_CR18","doi-asserted-by":"publisher","first-page":"155465","DOI":"10.1016\/j.prp.2024.155465","volume":"260","author":"N Ahmad","year":"2024","unstructured":"Ahmad N et al (2024) Fatty acid synthase: a key driver of ovarian cancer metastasis. Pathol Res Pract 260:155465","journal-title":"Pathol Res Pract"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41388-020-01516-4","volume":"40","author":"Q Zhang","year":"2021","unstructured":"Zhang Q et al (2021) ACSL1-mediated metastasis via protein myristoylation in ovarian cancer. Oncogene 40:97\u2013111","journal-title":"Oncogene"},{"key":"469_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/iub.1646","volume":"69","author":"MM Adeva-Andany","year":"2017","unstructured":"Adeva-Andany MM et al (2017) Significance of L-carnitine for human health. IUBMB Life 69:578\u2013594","journal-title":"IUBMB Life"},{"key":"469_CR21","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.18632\/oncotarget.6757","volume":"7","author":"H Shao","year":"2016","unstructured":"Shao H et al (2016) Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget 7:3832\u20133846","journal-title":"Oncotarget"},{"key":"469_CR22","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3892\/mmr.2014.2131","volume":"9","author":"Y Lin","year":"2014","unstructured":"Lin Y et al (2014) Silencing COX-2 inhibits ovarian cancer growth and invasion. Mol Med Rep 9:2499\u20132504","journal-title":"Mol Med Rep"},{"key":"469_CR23","doi-asserted-by":"publisher","first-page":"39582","DOI":"10.18632\/oncotarget.8659","volume":"7","author":"A Suri","year":"2016","unstructured":"Suri A et al (2016) Celecoxib suppresses tumor growth in ovarian cancer models. Oncotarget 7:39582\u201339594","journal-title":"Oncotarget"},{"key":"469_CR24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/onc.2014.85","volume":"34","author":"Z Wen","year":"2014","unstructured":"Wen Z et al (2014) Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene 34:1241\u20131252","journal-title":"Oncogene"},{"key":"469_CR25","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Lad\u00e1nyi","year":"2018","unstructured":"Lad\u00e1nyi A et al (2018) Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 37:2285\u20132301","journal-title":"Oncogene"},{"issue":"3","key":"469_CR26","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.bbrc.2017.12.086","volume":"495","author":"N Huangfu","year":"2018","unstructured":"Huangfu N et al (2018) LncRNA MALAT1 regulates oxLDL-induced CD36 expression via activating \u03b2-catenin. Biochem Biophys Res Commun 495(3):2111\u20132117","journal-title":"Biochem Biophys Res Commun"},{"key":"469_CR27","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498\u20131503","journal-title":"Nat Med"},{"key":"469_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"JL Goldstein","year":"2009","unstructured":"Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29:431\u2013438","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"469_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/1535370218760283","volume":"243","author":"L Zheng","year":"2018","unstructured":"Zheng L et al (2018) SREBP2 contributes to cisplatin resistance. Exp Biol Med (Maywood) 243:655\u2013662","journal-title":"Exp Biol Med (Maywood)"},{"key":"469_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/jcb.20113","volume":"92","author":"M Umezu-Goto","year":"2004","unstructured":"Umezu-Goto M et al (2004) Lysophosphatidic acid production and action in cancer. J Cell Biochem 92:1115\u20131140","journal-title":"J Cell Biochem"},{"key":"469_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cellsig.2018.01.007","volume":"44","author":"J Park","year":"2018","unstructured":"Park J et al (2018) LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA1 and LPA2. Cell Signal 44:138\u2013147","journal-title":"Cell Signal"},{"key":"469_CR32","doi-asserted-by":"publisher","first-page":"18739","DOI":"10.1073\/pnas.0604083103","volume":"103","author":"K Nakayama","year":"2006","unstructured":"Nakayama K et al (2006) A BTB\/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 103:18739\u201318744","journal-title":"Proc Natl Acad Sci USA"},{"key":"469_CR33","doi-asserted-by":"publisher","first-page":"9379","DOI":"10.3390\/ijms26199379","volume":"26","author":"N Nakayama","year":"2025","unstructured":"Nakayama N et al (2025) NAC1 regulates PCK2 and activates truncated gluconeogenesis. Int J Mol Sci 26:9379","journal-title":"Int J Mol Sci"},{"key":"469_CR34","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.3390\/ijms26104938","volume":"26","author":"S Shahataj","year":"2025","unstructured":"Shahataj S et al (2025) NAC1\/ACOX2 axis in ovarian neoplasms. Int J Mol Sci 26:4938","journal-title":"Int J Mol Sci"},{"key":"469_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/bjc.2012.246","volume":"107","author":"MT Rahman","year":"2012","unstructured":"Rahman MT et al (2012) Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Br J Cancer 107:300\u2013307","journal-title":"Br J Cancer"},{"key":"469_CR36","doi-asserted-by":"publisher","first-page":"285191","DOI":"10.1155\/2010\/285191","volume":"2010","author":"SM Ueda","year":"2010","unstructured":"Ueda SM et al (2010) FASN expression depends on NAC1 in ovarian carcinoma. J Oncol 2010:285191","journal-title":"J Oncol"},{"key":"469_CR37","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1126\/science.288.5475.2379","volume":"288","author":"TM Loftus","year":"2000","unstructured":"Loftus TM et al (2000) Reduced food intake with FASN inhibitors. Science 288:2379\u20132381","journal-title":"Science"},{"key":"469_CR38","doi-asserted-by":"publisher","first-page":"19970","DOI":"10.1074\/jbc.M402165200","volume":"279","author":"EK Kim","year":"2004","unstructured":"Kim EK et al (2004) C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 279:19970\u201319976","journal-title":"J Biol Chem"},{"key":"469_CR39","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"GS Falchook","year":"2021","unstructured":"Falchook GS et al (2021) First-in-human study of TVB-2640. EClinicalMedicine 34:100797","journal-title":"EClinicalMedicine"},{"key":"469_CR40","first-page":"1107","volume":"45","author":"Z Liu","year":"2015","unstructured":"Liu Z et al (2015) Obesity and ovarian cancer risk: meta-analysis. Jpn J Clin Oncol 45:1107\u20131115","journal-title":"Jpn J Clin Oncol"},{"key":"469_CR41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/jnci\/djae112","volume":"116","author":"EW Davis","year":"2024","unstructured":"Davis EW et al (2024) Body composition phenotypes and ovarian cancer mortality. J Natl Cancer Inst 116:1513\u20131524","journal-title":"J Natl Cancer Inst"},{"key":"469_CR42","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.3390\/jcm11113184","volume":"11","author":"N Nakayama","year":"2022","unstructured":"Nakayama N et al (2022) Muscle loss and prognosis in ovarian cancer. J Clin Med 11:3184","journal-title":"J Clin Med"},{"key":"469_CR43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2022.03.011","volume":"165","author":"S Stelen","year":"2022","unstructured":"Stelen S et al (2022) Exercise and dietary intervention during chemotherapy. Gynecol Oncol 165:619\u2013628","journal-title":"Gynecol Oncol"}],"container-title":["Medical Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00469-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00795-026-00469-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00469-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:49:27Z","timestamp":1787464167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00795-026-00469-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":43,"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s00795-026-00469-z","relation":{},"ISSN":["1860-1480","1860-1499"],"issn-type":[{"value":"1860-1480","type":"print"},{"value":"1860-1499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}